Chronic Spontaneous Urticaria Market
Report ID: SQMIG35H2612
Report ID: SQMIG35H2612
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35H2612 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
175
|Figures:
79
Global Chronic Spontaneous Urticaria Market size was valued at USD 3.06 Billion in 2024 and is poised to grow from USD 3.33 Billion in 2025 to USD 6.48 Billion by 2033, growing at a CAGR of 8.7% during the forecast period (2026-2033).
The growing importance of biologics among the growth drivers for the global CSU market is the key driver of growth, with improved efficacy compared with standard antihistamines translating directly into an increased willingness to pay and broader payer coverage. For instance, US data show 60% fewer emergency visits for patients switching to omalizumab, leading insurers to add the drug to formulary tiers and the launch of ligelizumab by manufacturers. Rising income levels in the Asia Pacific and use of teledermatology for diagnosis are leading to pools of patients. These pools can be used by companies to meet the unmet demand through clinical trials and partner networks, which in turn can further drive market growth.
How is AI-driven diagnostic automation shaping the chronic spontaneous urticaria market?
AI is contributing to diagnostic automation and changing the management of chronic spontaneous urticaria by rapidly identifying patterns in skin imaging and serum biomarker profiling. Machine learning models trained on large patient datasets would allow clinicians to discriminate between subtypes of autoimmunity and predict response to therapy, thereby reducing the need for trial-and-error prescribing. Integration with electronic health records will enable patient triage and personalized therapy choice. Investment and partnerships between biotech companies and health tech startups, and the acceleration of the deployment of next generation therapeutics is creating a burgeoning market for these tools. That leads to a more effective pipeline to match diagnostic accuracy with emerging biologic drugs.
In March 2025, Novartis bought the rights to Kyorin’s chronic spontaneous urticaria candidate. This acquisition is expected to leverage AI-powered image analysis to facilitate patient eligibility identification and enhance trial enrollment efficiency, thereby contributing to market growth and therapeutic advancement.
Market snapshot - (2026-2033)
Global Market Size
USD 3.06 Billion
Largest Segment
Antihistamine Therapy
Fastest Growth
Biologic Therapy
Growth Rate
8.7% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global chronic spontaneous urticaria market is segmented by treatment type, drug class, disease severity, route of administration, end user, distribution channel and region. Based on treatment type, the market is segmented into Antihistamine Therapy, Biologic Therapy, Immunosuppressive Therapy, Corticosteroid Therapy and Others. Based on drug class, the market is segmented into H1 Antihistamines, Monoclonal Antibodies, Leukotriene Receptor Antagonists, Immunosuppressants and Others. Based on disease severity, the market is segmented into Mild Chronic Spontaneous Urticaria, Moderate Chronic Spontaneous Urticaria and Severe Chronic Spontaneous Urticaria. Based on route of administration, the market is segmented into Oral and Injectable. Based on end user, the market is segmented into Hospitals, Dermatology Clinics, Allergy & Immunology Clinics and Ambulatory Care Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Antihistamine Therapy is the dominant segment, as it is the first-line approach for patients with intermittent and manageable symptoms, providing fast symptom relief with well established safety profile. Oral agents that can be initiated quickly in primary and specialty care, with less requirement for escalation, are preferred by clinicians. This entrenched clinical practice, combined with payer preference for cost effective options, sustains its market dominance across a range of care pathways and patient demographics.
The Biologic Therapy segment, however, is seeing the strongest growth momentum as emerging monoclonal antibodies target the underlying immune mechanisms providing relief for refractory cases. This is propelled by the rapid adoption of this space, helped by advances in precision medicine, increasing insurance coverage for high cost agents and increased physician awareness, making it a key driver of market expansion.
The antihistamines segment is expected to dominate the market owing to their immediate relief of itching and decades of proven clinical use making them the default prescription to most of the physicians. Their oral form is convenient for outpatient care, and their generic availability removes financial barriers, making them broadly accessible across care settings. These properties underscore their important position in the treatment pathway and patients’ adherence in the treatment of chronic spontaneous urticaria.
The Monoclonal Antibodies segment is predicted to expand at the fastest rate over the forecast period due to its ability to change the main cytokine pathways that result in persistent wheal formation. Ongoing clinical trials demonstrate superior efficacy for severe cases, which has resulted in guideline modifications and insurers’ inclusion of these agents. This innovation is driving demand and making biologics a transformational growth driver for the market.
To get detailed segments analysis, Request a Free Sample Report
The chronic spontaneous urticaria market in North America is the largest due to developed healthcare infrastructure, favorable reimbursement policies and high density of specialized dermatology and allergy centers. The access to advanced biologic therapies and strong clinical research networks help speed the adoption of new treatments. Pharmaceutical companies partner with academic institutions to build their pipeline and patient advocacy groups raise awareness of the disease and advocate for access to care. The regulatory environment also has fast-track review pathways for novel agents to shorten time to market and solidify the region’s leadership. The alignment of health technology assessment criteria among key economies is aiding cross-border market access. Moreover, digital health initiatives enhancing patient monitoring and adherence are further driving market momentum.
The United States Chronic Spontaneous Urticaria Market is driven by a strong ecosystem of specialists and an innovative payer environment that is quick to add novel biologics to formularies. Top research institutions are generating quality evidence of therapeutic benefit, and robust insurance coverage eliminates patient out-of-pocket barriers. Close cooperation between biotech companies and clinical centers accelerates the collection of real data, builds trust among clinicians, and improves the long-term adherence to treatment in different groups of patients.
Canada Chronic Spontaneous Urticaria Market benefits from a centralized drug reimbursement system focused on clinical efficacy and cost-effectiveness, facilitating timely access to advanced therapies. Provincial health authorities work hand-in-glove with specialty clinics to develop treatment guidelines and patient advocacy groups promote education and support programs. Such a partnership between manufacturers and academic hospitals provides a collaborative interface that promotes research and ensures that therapeutic advances are rapidly translated into clinical practice throughout the country.
The market for chronic spontaneous urticaria in Europe is expanding rapidly due to a connected healthcare system that combines strict therapeutic assessment with patient-centric access. Once clinical relevance has been demonstrated, strong national reimbursement policies in member states encourage uptake of innovative biologics. Cross-border collaborative research consortia allow sharing of data generation, speeding up the updating of guidelines and harmonising standards of practice. Advocacy networks promote increased disease awareness leading to earlier diagnosis and treatment initiation. The presence of leading pharmaceutical hubs paves the way for efficient regulatory pathways and continuous product pipeline enrichment, resulting in a vibrant environment for market growth and scientific progress across Europe. The convergence of health technology assessment criteria across major economies enables cross-border market entry, and digital health initiatives enhance patient monitoring and adherence, further fueling market momentum.
A strong network of university hospitals, at the forefront of clinical trial and guideline development, underpins the German chronic spontaneous urticaria market. Most of the approved biologics are covered by the country’s statutory health insurance scheme, so patients can get them quickly. Integrated care pathways coordinate care between allergists and dermatologists and national patient organizations increase awareness and support adherence programs. This synergistic environment allows for a high adoption of novel therapies in the German population.
Updates to the UK National Health Service Rapid Guideline Drivers of Chronic Spontaneous Urticaria Market Adopt new evidence-based treatments Add New Biologic Data To Provide State-Of-The-Art Options For Clinicians Strong academic-industry partnerships provide real-world evidence to help build confidence for payers. Today, patient advocacy groups have a seat at the table when policy is being discussed, fighting for better service delivery and faster access to therapies for people across the country.
The French chronic spontaneous urticaria market is expanding as France’s universal coverage system integrates biologics into its healthcare model. National health insurance is reimbursed on the basis of therapeutic value and this encourages judicious uptake. Hospital specialists and research institutes collaborate to enroll patients in clinical programs early and patient associations offer education and support. These joint efforts are part of the increasing acceptance of innovative therapies by French clinicians and patients.
Asia Pacific is increasingly gaining momentum in the chronic spontaneous urticaria space with the rapid adoption of innovative therapies and expanding specialist networks. These rare and chronic disease management programs by the government lay the foundation for a reimbursement system that can treat more patients with advanced biologics. Investing in clinical research infrastructure in the most important economies accelerates the generation of efficacy data specific to the region, which is then incorporated into localized guidelines to increase clinician confidence. Patient group awareness campaigns reduce diagnostic delays, while digital health platforms enhance treatment monitoring and adherence. The region’s growing pharmaceutical manufacturing capacity also shortens supply chains, helping to ensure that novel agents reach the clinical setting in a timely manner.
Japan’s Chronic Spontaneous Urticaria market is characterized by strong clinical expertise in allergy and dermatology, with nationwide insurance coverage for approved biologics. The country’s emphasis on precision medicine results in biomarker‐guided treatment strategies and academic institutions perform rigorous post‐marketing surveillance. Patient advocacy groups are actively involved in raising awareness of disease that helps in early intervention and adherence to the therapeutic regimens across Japanese healthcare facilities to improve patient outcomes.
South Korea’s regulatory environment promotes local clinical trials and expedites the review of biologic therapies, facilitating the country’s chronic spontaneous urticaria market. Proven effectiveness, fast access for patients, that is the basis for national health insurance coverage. Collaboration between tertiary hospitals and biotech companies to generate real world evidence enhances physicians’ confidence. In the Korean healthcare system, patient societies are educating the public, raising awareness, and allowing early diagnosis and long-term therapy adherence.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Awareness Among Patients
Expansion Of Biologic Therapeutics
High Cost Of Advanced Treatments
Limited Access In Emerging Regions
Request Free Customization of this report to help us to meet your business objectives.
Competitive Landscape Key players in pharma are Novartis, Sanofi, Regeneron and Celldex. These players are moving pipelines along with strategic M&A, partnership deals around new biologics, and oral agents. Emerging biotechnology companies are utilizing advanced immunology platforms to differentiate their pipelines and address the unmet needs of patients with chronic spontaneous urticaria.
Our Business Information Services team, ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) from SkyQuest, Collects, Collates, Correlates and Analyses the Data collected through Primary Exploratory Research backed by robust Secondary Desk research.
SkyQuest’s analysis shows that the chronic spontaneous urticaria market is driven by the rapid growth of biologic therapeutics that address refractory cases and receive strong support from payers. Increased awareness among patients leads to earlier diagnosis and drives demand for traditional antihistamines and newer agents. The Antihistamine Therapy segment continues to dominate the market share due to its well-established first-line position in all care settings. North America is leading the way in the field with a well-developed healthcare infrastructure, strong reimbursement channels and early adoption of biologics. High cost of advanced treatments is a major barrier limiting access in price-sensitive markets and broader uptake despite clinical advantages.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 3.06 Billion |
| Market size value in 2033 | USD 6.48 Billion |
| Growth Rate | 8.7% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Chronic Spontaneous Urticaria Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Chronic Spontaneous Urticaria Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Chronic Spontaneous Urticaria Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Chronic Spontaneous Urticaria Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Chronic Spontaneous Urticaria Market size was valued at USD 3.06 Billion in 2024 and is poised to grow from USD 3.33 Billion in 2025 to USD 6.48 Billion by 2033, growing at a CAGR of 8.7% during the forecast period (2026-2033).
The competitive landscape is shaped by major pharma players such as Novartis, Sanofi, Regeneron and Celldex, each accelerating pipelines through strategic M&A and partnership deals that target novel biologics and oral agents, while emerging biotech firms leverage advanced immunology platforms to differentiate their pipelines and capture unmet patient needs in chronic spontaneous urticaria. 'Novartis AG', 'F. Hoffmann-La Roche Ltd.', 'Sanofi S.A.', 'Regeneron Pharmaceuticals, Inc.', 'Celldex Therapeutics, Inc.', 'Jasper Therapeutics, Inc.', 'Allakos Inc.', 'Teva Pharmaceutical Industries Ltd.', 'LEO Pharma A/S', 'Kyowa Kirin Co., Ltd.', 'UCB S.A.', 'MoonLake Immunotherapeutics AG', 'Connect Biopharma Holdings Limited', 'ACELYRIN, Inc.', 'Blueprint Medicines Corporation', 'Kiniksa Pharmaceuticals International, plc', 'Astria Therapeutics, Inc.', 'Third Harmonic Bio, Inc.', 'Nektar Therapeutics', 'Celon Pharma S.A.'
Increasing awareness among patients about chronic spontaneous urticaria leads to earlier diagnosis, which encourages prompt initiation of appropriate therapy. Physicians become more likely to consider modern antihistamines and targeted biologics, widening the therapeutic landscape. Patient advocacy groups disseminate educational material, fostering confidence in seeking specialist care. This heightened engagement drives demand for approved products and stimulates research interest, thereby supporting market expansion. The overall environment becomes more conducive to adoption of innovative treatments, reinforcing growth momentum across the sector and encouraging further investment by pharmaceutical firms.
Personalized Biologic Therapies: The market is shifting toward highly individualized biologic treatments that target specific immune pathways implicated in chronic spontaneous urticaria, enabling clinicians to tailor therapy based on patient phenotype and disease severity. This approach reduces trial‑and‑error prescribing, improves long‑term disease control, and enhances patient quality of life. Manufacturers are investing in biomarker research and companion diagnostics, fostering a collaborative ecosystem of labs, specialists, and payers that prioritizes precision care over conventional, one‑size‑fits‑all regimens while supporting sustainable reimbursement models worldwide and innovation.
Why does North America Dominate the Global Chronic Spontaneous Urticaria Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
